Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

A new study has uncovered the role of ACC1 enzyme in the regulation of glucagon secretion for the first time. This raises the prospect of a potential new therapeutic target in the context of type 2 diabetes and metabolic disorders characterised by hyperglycaemia.

Side by side pancreatic islets demonstrating prevalence of glucagon in normal animals and heavily reduced glucagon when ACC1 is knocked out
Pancreatic islets stained for insulin (red) and glucagon (green) - glucagon is more prevalent in left hand islet (control animals) vs the right hand islet (KO animals) where ACC1 is knocked out

The study was carried out between Department of Physiology, Anatomy & Genetics (DPAG), Oxford Centre for Diabetes, Endocrinology and Metabolism (Radcliffe Department of Medicine), and the University of Dundee, performed as part of the Oxford Novo Nordisk Fellowship Programme, with experimental work also performed at the Novo Nordisk Research Centre Oxford.

Led by Dr Anna Veprik (Radcliffe Department of Medicine) and Novo Nordisk project leaders Associate Professor Heidi de Wet (DPAG) and Dr James Cantley (University of Dundee), the study uncovered the essential role of the enzyme Acetyl-CoA-Carboxylase 1 (ACC1) in the function of pancreatic alpha cells and glucagon secretion. After an influx of nutrients enters the body following feeding, ACC1 is the first step in pathway called ‘de-novo lipogenesis’, which converts the available glucose from the nutrients into lipids to be stored for future use. In contrast to the hepatocytes of the liver, alpha cells in the pancreas are not known for substantial lipid storage. The research shows that ACC1 is acting as a central ‘nutrient availability sensor’ for the alpha cells, which is used to calculate the right amount of glucagon that needs to be released.

Read the full story on the DPAG website

Similar stories

New research reveals relationship between particular brain circuits and different aspects of mental wellbeing

Researchers at the University of Oxford have uncovered previously unknown details about how changes in the brain contribute to changes in wellbeing.

Night-time blood pressure assessment is found to be important in diagnosing hypertension

Around 15% of people aged 40-75 may have a form of undiagnosed high blood pressure (hypertension) that occurs only at night-time. Because they do not know about this, and therefore are not being treated for it, they are at a higher risk of cardiovascular disease such as stroke, heart failure, and even death, suggests new research from the University of Oxford published in the British Journal of General Practice.

Major new NIHR Global Health Research Unit to focus on data science and genomic surveillance of antimicrobial resistance

The Centre for Genomic Pathogen Surveillance, part of the Big Data Institute at the University of Oxford, has been awarded funding worth £7m for their work as an NIHR Global Health Research Unit (GHRU) for the next five years. The Centre’s research and capacity building work focuses on delivering genomics and enabling data for the surveillance of antimicrobial resistance (AMR).

How artificial intelligence is shaping medical imaging

Dr Qiang Zhang of the Radcliffe Department of Medicine explains how artificial intelligence is being used to help researchers and physicians interpret medical imaging.

Researchers describe how cancer cells can defend themselves from the consequences of certain genetic defects

Researchers in Department of Physiology, Anatomy and Genetics have identified a rescue mechanism that allows cancers to overcome the consequences of inactivating mutations in critically important genes.